L'angolo dell'immunologo
Le citochine: da mediatori della flogosi a bersaglio della terapia
TARCISIO NOT, EMANUELE BURATTI, IRENE BERTI, CHIARA TREVISIOL, ELENA NERI, ALBERTO TOMMASINI
Laboratorio Immunologico, Istituto di Clinica Pediatrica, IRCCS “Burlo Garofolo”, Trieste
Febbraio 1998 - pagg. 103 -107
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
causes
growth impairment in transgenic mice
through a decrease in insulin-like
growth factor-I. A model for stunted
growth in children with chronic inflammation.
J Clin Invest 1997.
2. Cohen IR: The Th1/Th2 dichotomy, hsp60 autoimmunity, and type I diabetes. Clin Immunol Immunopathol 84, 103-106, 1997.
3. Genain CP: Late complications of immune deviation therapy in a nonhuman primate. Science 274, 2054-2057, 1996.
4. Wolvers DAW: Mucosal tolerance is associated with, but independent of, upregulation Th2 responses. Immunology 92, 328-333, 1997.
5. Niederau et al: Inflammatory mediators and acute phase proteins in patients with Crohn disease and ulcerative colitis. Hepatogastroenterology 44, 90-107, 1997.
6. Nakamura M et al: Cytokine production in patients with inflammatory bowel disease. GUT 33, 933-937, 1992.
7. Beckham et al: Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor alpha, soluble interleukin-2 receptor, soluble CD4/CD8 ratio, neopterin, and fibrin Ddimer to traditional severity and functional measures. J Clin Immunol 12, 353- 361, 1992.
8. Saxne T et al: Detection of tumor necrosis alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31, 104- 105, 1988.
9. Houssiau FA et al: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4, 393- 395, 1995.
10. Leung DJM: Immunologic basis of chronic allergic diseases: clinical messages from the laboratory bench. Pediatr Res 42, 559-568, 1997. 11 Heumann D, Glauser MP: Pathogenesis of sepsis. Sci Am Med 1, 28-37, 1994.
12. Azuma H: Clinical significance of cytokine (IL-6 and TNFa) measurement for detection of meningitis. J Pediatr 131, 463, 1997.
13. Rollnik JD: Biologically active TGF-b 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients. Acta Neurol Scand 96, 101-105, 1997.
14. Hussain MJ et al: Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 39, 60-69, 1996.
15. Epstein FH: Nuclear factor-kB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336, 1066-1071, 1997.
16. Wilkens T, Rijk RD: Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 18, 418-424, 1997.
17. Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of an ormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24, 181-197, 1949.
18. Eigler A et al: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18, 487-492, 1997.
19. Moreira AL et al: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 77, 1675-80, 1993.
20. McHugh SM, Rowland TL: Thalidomide and derivatives: immunological investigations of tumor necrosis factor alpha (TNF-a) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 110, 151-154, 1997.
21. Fernandez LP et al: Does thalidomide effect IL-2 response and production? Exp Hematol 23, 978-85, 1995.
22. Abraham et al: P55 tumor necrosis factor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 277, 1531-1538, 1997.
23. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337, 141-147, 1997.
24. Targan SR, Hanauer SB et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 337, 1029-1033, 1997.
25. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J et al: Treatment of Crohn’s disease with anti- tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135, 1995.
26. Firestein GS, Zvaifler NJ: Anticytokine therapy in rheumatoid arthritis. N Engl J Med 337, 195-197, 1997.
27. Van Deventer SJ et al: Multiple doses of interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 113, 383-389, 1997.
28. Sieper et al: Oral type II collagen treatment in early rheumatoid arthritis. A double blind, placebo controlled, randomized trial. Arthritis Rheum 39, 41-51, 1996.
2. Cohen IR: The Th1/Th2 dichotomy, hsp60 autoimmunity, and type I diabetes. Clin Immunol Immunopathol 84, 103-106, 1997.
3. Genain CP: Late complications of immune deviation therapy in a nonhuman primate. Science 274, 2054-2057, 1996.
4. Wolvers DAW: Mucosal tolerance is associated with, but independent of, upregulation Th2 responses. Immunology 92, 328-333, 1997.
5. Niederau et al: Inflammatory mediators and acute phase proteins in patients with Crohn disease and ulcerative colitis. Hepatogastroenterology 44, 90-107, 1997.
6. Nakamura M et al: Cytokine production in patients with inflammatory bowel disease. GUT 33, 933-937, 1992.
7. Beckham et al: Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor alpha, soluble interleukin-2 receptor, soluble CD4/CD8 ratio, neopterin, and fibrin Ddimer to traditional severity and functional measures. J Clin Immunol 12, 353- 361, 1992.
8. Saxne T et al: Detection of tumor necrosis alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum 31, 104- 105, 1988.
9. Houssiau FA et al: Serum interleukin 10 titers in systemic lupus erythematosus reflect disease activity. Lupus 4, 393- 395, 1995.
10. Leung DJM: Immunologic basis of chronic allergic diseases: clinical messages from the laboratory bench. Pediatr Res 42, 559-568, 1997. 11 Heumann D, Glauser MP: Pathogenesis of sepsis. Sci Am Med 1, 28-37, 1994.
12. Azuma H: Clinical significance of cytokine (IL-6 and TNFa) measurement for detection of meningitis. J Pediatr 131, 463, 1997.
13. Rollnik JD: Biologically active TGF-b 1 is increased in cerebrospinal fluid while it is reduced in serum in multiple sclerosis patients. Acta Neurol Scand 96, 101-105, 1997.
14. Hussain MJ et al: Elevated serum levels of macrophage-derived cytokines precede and accompany the onset of IDDM. Diabetologia 39, 60-69, 1996.
15. Epstein FH: Nuclear factor-kB - A pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336, 1066-1071, 1997.
16. Wilkens T, Rijk RD: Glucocorticoids and immune function: unknown dimensions and new frontiers. Immunol Today 18, 418-424, 1997.
17. Hench PS, Kendall EC, Slocumb CH, Polley HF: The effect of an ormone of the adrenal cortex (17-hydroxy-11-dehydrocorticosterone; compound E) and of pituitary adrenocorticotropic hormone on rheumatoid arthritis. Proc Staff Meet Mayo Clin 24, 181-197, 1949.
18. Eigler A et al: Taming TNF: strategies to restrain this proinflammatory cytokine. Immunol Today 18, 487-492, 1997.
19. Moreira AL et al: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 77, 1675-80, 1993.
20. McHugh SM, Rowland TL: Thalidomide and derivatives: immunological investigations of tumor necrosis factor alpha (TNF-a) inhibition suggest drugs capable of selective gene regulation. Clin Exp Immunol 110, 151-154, 1997.
21. Fernandez LP et al: Does thalidomide effect IL-2 response and production? Exp Hematol 23, 978-85, 1995.
22. Abraham et al: P55 tumor necrosis factor fusion protein in the treatment of patients with severe sepsis and septic shock. A randomized controlled multicenter trial. JAMA 277, 1531-1538, 1997.
23. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM et al: Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 337, 141-147, 1997.
24. Targan SR, Hanauer SB et al: A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn’s disease. N Engl J Med 337, 1029-1033, 1997.
25. Van Dullemen HM, Van Deventer SJH, Hommes DW, Bijl HA, Jansen J et al: Treatment of Crohn’s disease with anti- tumor necrosis factor chimeric monoclonal antibody (cA2). Gastroenterology 109, 129-135, 1995.
26. Firestein GS, Zvaifler NJ: Anticytokine therapy in rheumatoid arthritis. N Engl J Med 337, 195-197, 1997.
27. Van Deventer SJ et al: Multiple doses of interleukin 10 in steroid-refractory Crohn’s disease. Crohn’s Disease Study Group. Gastroenterology 113, 383-389, 1997.
28. Sieper et al: Oral type II collagen treatment in early rheumatoid arthritis. A double blind, placebo controlled, randomized trial. Arthritis Rheum 39, 41-51, 1996.